Mitsubishi UFJ Asset Management UK Ltd. Purchases New Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Key Points

• Mitsubishi UFJ Asset Management UK Ltd. has acquired a new stake in ANI Pharmaceuticals, purchasing 5,000 shares valued at approximately $335,000 in the first quarter of 2023.
• Institutional investors have significantly increased their holdings in ANI Pharmaceuticals, with Principal Financial Group Inc. growing its stake by 68.3% to own 157,798 shares.
• ANI Pharmaceuticals reported a quarterly earnings result of $1.80 EPS, outperforming analyst expectations and marking a 53.2% year-over-year increase in revenue.

Mitsubishi UFJ Asset Management UK Ltd. purchased a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 5,000 shares of the specialty pharmaceutical company's stock, valued at approximately $335,000.

Other institutional investors also recently bought and sold shares of the company. Principal Financial Group Inc. grew its holdings in ANI Pharmaceuticals by 68.3% in the first quarter. Principal Financial Group Inc. now owns 157,798 shares of the specialty pharmaceutical company's stock valued at $10,565,000 after purchasing an additional 64,021 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in ANI Pharmaceuticals by 53.3% in the first quarter. Allspring Global Investments Holdings LLC now owns 8,949 shares of the specialty pharmaceutical company's stock valued at $599,000 after purchasing an additional 3,112 shares during the period. GAMMA Investing LLC grew its holdings in ANI Pharmaceuticals by 163.8% in the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock valued at $95,000 after purchasing an additional 881 shares during the period. Stifel Financial Corp grew its holdings in ANI Pharmaceuticals by 20.4% in the fourth quarter. Stifel Financial Corp now owns 8,424 shares of the specialty pharmaceutical company's stock valued at $466,000 after purchasing an additional 1,425 shares during the period. Finally, Northern Trust Corp grew its holdings in ANI Pharmaceuticals by 9.0% in the fourth quarter. Northern Trust Corp now owns 204,345 shares of the specialty pharmaceutical company's stock valued at $11,296,000 after purchasing an additional 16,820 shares during the period. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 400 shares of the stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $64.88, for a total value of $25,952.00. Following the transaction, the vice president owned 78,945 shares in the company, valued at approximately $5,121,951.60. This represents a 0.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 11.10% of the company's stock.

Analyst Ratings Changes

Several brokerages have commented on ANIP. Guggenheim reissued a "buy" rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Truist Financial lifted their price target on ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a research note on Monday. Piper Sandler reaffirmed an "overweight" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. HC Wainwright reissued a "buy" rating and set a $93.00 price objective (up previously from $84.00) on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Finally, Wall Street Zen lowered ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, April 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $84.75.

ANI Pharmaceuticals Price Performance

NASDAQ:ANIP opened at $88.74 on Thursday. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $90.23. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39. The company has a market capitalization of $1.92 billion, a P/E ratio of -115.25 and a beta of 0.61. The stock's fifty day moving average is $66.74 and its two-hundred day moving average is $64.42.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%. The company had revenue of $211.37 million for the quarter, compared to the consensus estimate of $187.18 million. During the same quarter in the previous year, the business earned $1.02 earnings per share. The company's revenue for the quarter was up 53.2% on a year-over-year basis. Equities analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.